Suven Life Sciences Announces Unaudited Financial Results for Quarter Ended June 30, 2026; Clinical Pipeline Updates Provided

Suven Life Sciences Announces Unaudited Financial Results for Quarter Ended June 30, 2026; Clinical Pipeline Updates Provided​

Hyderabad: Suven Life Sciences Limited today released its unaudited financial results and operational updates for the quarter ended June 30, 2026. The results were reviewed by the company’s Audit Committee and approved by the Board of Directors at a meeting held on August 6, 2026.

The company reports that it has only one business segment: Research & Development.

Financial Performance Overview​

The unaudited financial statements for the quarter ended June 30, 2026, have been prepared in accordance with Indian Accounting Standards (Ind AS).

Key financial metrics across both standalone and consolidated results are detailed below, with figures presented in Rs. Lakhs:

Table 1: Financial Highlights (Rs. in Lakhs)

Corporate Actions and Equity Updates​

The company provided updates regarding several corporate actions related to its share capital and employee stock options.

For the quarter ended June 30, 2026:

• Employee Stock Option Scheme (ESOP): The company recognized an employee benefit expense (EBP) of Rs. 145.54 lakhs in accordance with Ind AS I 02 Share-based Payment due to the implementation of the SLSL Employee Stock Option Scheme 2020, under which 1,33,200 stock options were granted on May 13, 2026.
• Equity Allotment: The company allotted 2,71,970 equity shares of Rs. 1 each pursuant to the exercise of stock options by employees under the Employee Stock Options Scheme 2020.
• Preferential Issue: As of June 30, 2026, the company had received the entire amount of Rs. 85,764.02 lakhs from warrant holders concerning the issue of 6,40,02,999 convertible warrants, which were initially approved in May 2025 and subsequently approved by shareholders in June 2025. During the quarter, an amount of Rs. 9,331.49 lakhs was received for 1,85,70,133 warrants for which allotment is pending.

Clinical Development Pipeline Update​

The company highlighted the status of its clinical development pipeline in Central Nervous System (CNS) disorders:

• SUVN-502 (Masupirdine): The drug achieved a 95% Enrollment milestone in the Global Phase 3 Trial for Agitation in Alzheimer's Dementia. Patient enrolment is expected to be completed by the end of September 2026, with database lock and reporting potentially occurring in Q2, 2027 calendar year.
• SUVN-G3031 (Samelisant): Global Phase 3 clinical trials were initiated in April 2026 for treatment of EDS in Narcolepsy.
• SUVN-911 (Ropanicant): The company successfully completed the Phase 2b clinical trial evaluating the efficacy and safety of Ropanicant in Major Depressive Disorder (MDD).
• SUVN-D4010 (Usmarapride): The design for a Phase 2 Proof of Concept study is being finalized to target cognitive impairment in psychiatric disorder.
• SUVN-I6107: A Phase 1 study establishing safety and pharmacokinetics has been completed, and preparations are underway for a Phase 2 clinical study.

The statements were reviewed by the Independent Auditors from KARVY & CO., and confirmed compliance with relevant accounting standards.